Compare OCCI & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OCCI | MIST |
|---|---|---|
| Founded | N/A | 2003 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 139.4M | 163.2M |
| IPO Year | N/A | N/A |
| Metric | OCCI | MIST |
|---|---|---|
| Price | $4.52 | $2.29 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $6.33 |
| AVG Volume (30 Days) | 115.8K | ★ 5.3M |
| Earning Date | 12-11-2023 | 11-12-2025 |
| Dividend Yield | ★ 24.32% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $10.19 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.47 | $0.63 |
| 52 Week High | $10.15 | $3.06 |
| Indicator | OCCI | MIST |
|---|---|---|
| Relative Strength Index (RSI) | 36.49 | 45.30 |
| Support Level | $4.75 | $1.61 |
| Resistance Level | $5.09 | $3.06 |
| Average True Range (ATR) | 0.14 | 0.31 |
| MACD | -0.02 | -0.04 |
| Stochastic Oscillator | 6.15 | 46.21 |
OFS Credit Co Inc is a non-diversified, closed-end management investment company. Its investment objective is to generate current income, with a secondary objective to generate capital appreciation through investment in collateralized loan obligation (CLO) equity and debt securities. The company invests in floating rate credit instruments and other structured credit investments, including; collateralized loan obligation (CLO) debt and subordinated (i.e., residual or equity) securities; traditional corporate credit investments, including leveraged loans and high yield bonds; opportunistic credit investments, including stressed and distressed credit situations and long/short credit investments; and other credit-related instruments.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).